Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders

Gregory de Boer, Robertus Maria Alfonsius de Bie, Bart Erik Kris Sylvain Swinnen*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Extrapyramidal hyperkinetic movement disorders comprise a broad range of phenotypic phenomena, including chorea, dystonia, and tics. Treatment is generally challenging and individualized, given the overlapping phenomenology, limited evidence regarding efficacy, and concerns regarding the tolerability and safety of most treatments. Over the past decade, the treatment has become even more intricate due to advancements in the field of deep brain stimulation as well as optimized dopamine-depleting agents. Here, we review the current evidence for treatment modalities of extrapyramidal hyperkinetic movement disorders and provide a comprehensive and practical overview to aid the choice of therapy. Mechanism of action and practical intricacies of each treatment modality are discussed, focusing on dosing and adverse effect management. Finally, future therapeutic developments are also discussed.

Original languageEnglish
Pages (from-to)2284-2297
Number of pages14
JournalCurrent Neuropharmacology
Volume22
Issue number14
DOIs
Publication statusPublished - 20 May 2024

Keywords

  • botulinum toxin
  • deep brain stimulation
  • Extrapyramidal
  • hyperkinetic
  • medication
  • movement disorders
  • neuropharmacology
  • treatment

Fingerprint

Dive into the research topics of 'Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders'. Together they form a unique fingerprint.

Cite this